These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22846628)

  • 1. Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia.
    Koedam EL; van der Vlies AE; van der Flier WM; Verwey NA; Koene T; Scheltens P; Blankenstein MA; Pijnenburg YA
    Alzheimers Dement; 2013 May; 9(3):269-75. PubMed ID: 22846628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic normal-pressure hydrocephalus, cerebrospinal fluid biomarkers, and the cerebrospinal fluid tap test.
    Kang K; Ko PW; Jin M; Suk K; Lee HW
    J Clin Neurosci; 2014 Aug; 21(8):1398-403. PubMed ID: 24836892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease.
    Haldenwanger A; Eling P; Kastrup A; Hildebrandt H
    J Alzheimers Dis; 2010; 22(3):971-80. PubMed ID: 20858947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease.
    Körtvélyessy P; Gukasjan A; Sweeney-Reed CM; Heinze HJ; Thurner L; Bittner DM
    J Alzheimers Dis; 2015; 46(2):375-80. PubMed ID: 25777512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
    Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
    Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
    Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
    Stomrud E; Hansson O; Zetterberg H; Blennow K; Minthon L; Londos E
    Arch Neurol; 2010 Feb; 67(2):217-23. PubMed ID: 20142530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia.
    Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Boulanghien J; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Perret-Liaudet A; Touchon J; Lehmann S
    J Alzheimers Dis; 2011; 26(3):553-63. PubMed ID: 21709372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Otto M; Kornhuber J; Rüther E; Wiltfang J
    Dement Geriatr Cogn Disord; 2011; 31(1):37-44. PubMed ID: 21135556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
    J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical AD predicts decline in memory and executive functions in subjective complaints.
    van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM
    Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grey matter and cognitive patterns in cognitive impaired subjects using CSF biomarker cut-offs.
    Miralbell J; Spulber G; Hooshmand B; Besga A; Mataró M; Cedazo-Minguez A; Kivipelto M; Wahlund LO
    J Alzheimers Dis; 2012; 29(4):741-9. PubMed ID: 22330819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?
    Mitchell AJ; Monge-Argilés JA; Sánchez-Paya J
    Pract Neurol; 2010 Aug; 10(4):202-7. PubMed ID: 20647526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia.
    Marelli C; Hourregue C; Gutierrez LA; Paquet C; Menjot de Champfleur N; De Verbizier D; Jacob M; Dubois J; Maleska AM; Hirtz C; Navucet S; Bennys K; Dumurgier J; Cognat E; Berr C; Magnin E; Lehmann S; Gabelle A
    J Alzheimers Dis; 2020; 74(3):903-911. PubMed ID: 32083577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
    Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
    Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.